This Month’s Guest Editors
Dr. Melissa Mazan
Dr. Melissa Mazan, DVM, Diplomate ACVIM, is an Associate Professor and Director of the Equine Sports Medicine program at the Cummings School of Veterinary Medicine’s Hospital for Large Animals. Lung function, she notes, is essential to the success of equine athletes, and optimizing performance for competing horses is an important goal for hers. Dr. Mazan has extensive experience in the area of equine inflammatory airway disease, which affects as many as 80 percent of stabled horses and has provided pathways to better understanding similar human diseases, such as emphysema.
Dr. Daniela Bedenice
Dr. Bedenice, Dr. Med. Vet, Diplomate ACVIM, Diplomate ACVECC, joined the Tufts faculty following specialized training in large animal critical care and respiratory medicine. Dr. Bedenice became board certified in the specialty of large animal internal medicine in 2002, followed by large animal emergency and critical care in 2005. She works as an Assistant Professor in the Department of Clinical Sciences at Tufts, which combines teaching, research and a clinical referral service in the field of camelid and equine health care. Her special interests lie in comparative respiratory medicine, early disease identification and management, as well as newborn and adult intensive care. In collaboration with Drs. Hoffman and Mazan, Dr. Bedenice has been integrally involved in the characterization of lung disease, as well as development and validation of pulmonary function testing across species.
Dr. Andrew Hoffman
An expert in equine lung function, Dr. Andrew Hoffman, DVM, DVSc, Diplomate ACVIM, is a Professor, researcher, and clinician at the Cummings School of Veterinary Medicine’s Hospital for Large Animals. Dr. Hoffman has spearheaded the development of non-invasive lung function testing of animals at the Cummings School, including horses, dogs, cats, camelids and mice. His current research focuses on new approaches to cell-based therapy for chronic lung diseases, such as emphysema and pulmonary fibrosis, and has led to an important therapy for emphysema that has completed Phase I and II clinical trials in humans. His latest research centers around which cells in the lung have potential to repair damaged tissue, including stem cells derived from lung tissue.<!